Efficacy of Combined Dabrafenib and Trametinib Therapy in BRAFV600E Mutant Intrahepatic Cholangiocarcinoma with a Neurofibromatosis Type 2 Mutation.

We herein report a 41-year-old woman with BRAFV600E-mutated intrahepatic cholangiocarcinoma and a concurrent loss of function in NF2. The patient had a large liver tumor, multiple lymph nodes, and metastases to the lungs and pleura. She underwent six cycles of gemcitabine, cisplatin, and durvalumab but was refractory to this treatment. Comprehensive genomic profiling revealed a BRAFV600E mutation along with a loss of function in NF2. The patient was treated with a combination of oral dabrafenib and trametinib therapy. After two months, imaging showed reduced pleural effusion, tumor shrinkage, symptom resolution, and improved performance status, without significant side effects.